CEO Itescu needs to go, page-281

righto se here is my next question:

if, as a number of posters have pointed out, there was little point in doing a trial until potency and manufacturing was signed off and so actually NOT doing what the FDA asked for was prudent cash management, where was the messaging from management et al that this resubmission was more likely iterative than definitive?

it's all well and good to point to shareholder expectations after the fact, but that messaging comes from them. that's really all we have and I don't remember them saying "hold you clogs we probably need another round after that cos we gotta get the manufacturing signed off"

All I remember reading was look at this magnificent data we have and we're going to resubmit for approval.